PTGX
Protagonist Therapeutics Inc.
$76.40
-$2.22(-2.82%)
63
Overall
55
Value
66
Tech
68
Quality
Market Cap
$4.88B
Volume
541.57K
52W Range
$33.31 - $93.25
Target Price
$80.69
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | -- | $20.1M | $30.9M | $64.0K | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | ||
| Total Revenue | -- | $20.1M | $30.9M | $64.0K | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | -- | $20.1M | -- | $64.0K | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $-32.7M | $-58.0M | $-73.2M | $80.8M | $93.1M | $153.2M | $158.0M | $153.7M | $181.6M | ||
| Research & Development | $25.7M | $46.2M | $59.5M | $65.0M | $74.5M | $126.0M | $126.2M | $120.2M | $138.1M | ||
| Research Expense | $25.7M | $46.2M | $59.5M | $65.0M | $74.5M | $126.0M | $126.2M | $120.2M | $138.1M | ||
| Selling, General & Administrative | $7.0M | $11.8M | $13.7M | $15.7M | $18.6M | $27.2M | $31.7M | $33.5M | $43.5M | ||
| General & Administrative Expenses | $7.0M | $11.8M | $13.7M | $15.7M | $18.6M | $27.2M | $31.7M | $33.5M | $43.5M | ||
| Salaries & Wages | $-2.1M | $-4.2M | $-30.9M | $-231.0K | $7.9M | $16.4M | $24.2M | $29.3M | $37.6M | ||
| Depreciation & Amortization | $-317.0K | $-406.0K | $-527.0K | $703.0K | $789.0K | $813.0K | $1.0M | $977.0K | $894.0K | ||
| Depreciation & Amortization | $-317.0K | $-406.0K | $-527.0K | $703.0K | $789.0K | $813.0K | $1.0M | $977.0K | $894.0K | ||
| Amortization | -- | -- | -- | $13.0K | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-619.0K | $-3.3M | $-3.9M | $-7.0M | $-7.1M | $-13.3M | $-2.9M | $-2.7M | $-3.5M | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-32.7M | $-58.0M | $-42.3M | $-80.5M | $-64.5M | $-125.8M | $-131.4M | $-93.7M | $252.8M | ||
| EBITDA | $-36.7M | $-35.9M | $-39.0M | $-75.8M | $-61.5M | $-123.1M | $-124.0M | $-75.6M | $282.3M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $169.0K | $598.0K | -- | -- | -- | -- | ||
| Intinc | $242.0K | $940.0K | $2.6M | $2.8M | $900.0K | $443.0K | $4.1M | $14.9M | $26.3M | ||
| Net Non-Operating Interest Income/Expense | $242.0K | $940.0K | $2.6M | $2.6M | $302.0K | $443.0K | $4.1M | $14.9M | $26.3M | ||
| Other Income/Expense | $34.0K | $-20.1M | $20.0K | $1.0K | $631.0K | $149.0K | $-80.0K | $201.0K | $-250.0K | ||
| Other Special Charges | $-34.0K | $20.1M | $-20.0K | $-1.0K | $-631.0K | $-149.0K | $-80.0K | $-201.0K | $250.0K | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-37.2M | $-37.0M | $-39.7M | $-77.7M | $-64.2M | $-125.8M | $-127.4M | $-79.0M | $279.4M | ||
| Pre-Tax Income | $-37.2M | $-37.0M | $-39.7M | $-77.9M | $-64.8M | $-125.6M | $-127.4M | $-79.0M | $279.4M | ||
| INCOME TAX | |||||||||||
| Tax Provision | -- | -- | $-799.0K | $-691.0K | $1.3M | -- | -- | -- | $4.2M | ||
| NET INCOME | |||||||||||
| Net Income | $-37.2M | $-37.0M | $-38.9M | $-77.2M | $-66.2M | $-125.6M | $-127.4M | $-79.0M | $275.2M | ||
| Net Income (Continuing Operations) | $-37.2M | $-37.0M | $-38.9M | $-77.2M | $-66.2M | $-125.6M | $-127.4M | $-79.0M | $275.2M | ||
| Net Income (Discontinued Operations) | $-37.2M | $-37.0M | $-38.9M | $-77.2M | $-66.2M | $-125.6M | $-127.4M | $-79.0M | $275.2M | ||
| Net Income (Common Stockholders) | $-37.2M | $-37.0M | $-38.9M | $-77.2M | $-66.2M | $-125.6M | $-127.4M | $-79.0M | $275.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $276.6M | ||
| TOTALS | |||||||||||
| Total Expenses | $-32.7M | $-58.0M | $-73.2M | $80.8M | $93.1M | $153.2M | $158.0M | $153.7M | $181.6M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $6.5M | $17.7M | $22.4M | $25.9M | $34.4M | $46.3M | $49.0M | $56.8M | $61.6M | ||
| Average Shares Outstanding (Diluted) | $6.4M | $17.7M | $22.4M | $25.9M | $34.4M | -- | $49.0M | $56.8M | $65.1M | ||
| Shares Outstanding | $16.8M | $21.1M | $23.3M | $27.3M | $43.8M | $48.4M | $51.3M | $58.3M | $61.4M | ||
| Basic EPS | -- | -- | -- | $-2.98 | $-1.92 | $-2.71 | $-2.6 | $-1.39 | $4.47 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-2.98 | $-1.92 | $-2.71 | $-2.6 | $-1.39 | $4.47 | ||
| Diluted EPS | $-5.8 | $-2.09 | $-1.74 | $-2.98 | $-1.92 | $-2.71 | $-2.6 | $-1.39 | $4.23 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-2.6 | $-1.39 | $4.23 | ||
| OTHER METRICS | |||||||||||
| Accretion On Preferred Stock | $-558.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Income From Other Gains Losses | $-4.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $7.0M | $11.8M | $13.7M | $15.7M | $18.6M | $27.2M | $31.7M | $33.5M | $43.5M | ||
| Otherunder Preferred Stock Dividend | $-558.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $-558.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $7.0M | $11.8M | $13.7M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PTGX | $76.40 | -2.8% | 541.57K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Protagonist Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW